Click Here to return To Results

 

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010 See this aricle in Pubmed Article Abstract Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and MRI measures of disease activity at 96 weeks. The benefits need to be weighed against the risks.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction cladribine complications disability,neurological efficacy herpes zoster immunosuppressive agents lymphopenia MRI MRI,abnormal multiple sclerosis multiple sclerosis,relapsing multiple sclerosis,treatment of safety treatment of neurologic disorder

Click Here to return To Results